Sanofi, tolebrutinib and multiple sclerosis
Sanofi's tolebrutinib drug delays progressive MS by 31% in trial
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Sanofi’s Tolebrutinib Delays MS Progression in Phase III Study Following Earlier Flops
The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of back-to-back failures in which tolebrutinib was unable to improve relapse rates in patients with relapsing MS.
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was able to delay the time to six-month disability progression by 31% compared to placebo in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Sanofi says tolebrutinib drug delayed progressive MS by 31%
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Cleveland Clinic researcher advises Sanofi on multiple sclerosis drug that slows disease’s progression
Tolebrutinib delayed the onset of disability progression by 31% for patients with a type of the disease called non-relapsing secondary progressive MS, according to data from a late stage trial presented Friday, Sept. 20, at a research congress in Copenhagen. The results confirm topline findings published on Sept. 2.
Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows
Sanofi SA (NASDAQ:SNY) released data from the HERCULES phase 3 study of tolebrutinib for non-relapsing secondary progressive multiple sclerosis (nrSPMS). The data demonstrated that tolebrutinib delayed the time to onset of 6-month confirmed disability progression (CDP) by 31% compared to placebo (HR 0.
Sanofi’s Multiple Sclerosis Drug Slows Disease’s Progression
Sanofi’s experimental drug for a form of multiple sclerosis delayed the progression of disability by nearly a third, providing hope for patients for whom there’s currently no treatment.
New multiple sclerosis drug by Sanofi delays progressive form of disease by 31 per cent in trial
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection
Medpage Today on MSN1d
Tolebrutinib Slows Disability in Non-Relapsing Secondary Progressive MS
Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...
FierceBiotech23h
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings
Sanofi has shared data from the phase 3 HERCULES trial that could rescue its multiple sclerosis (MS) drug candidate ...
Medscape14h
Novel Agent First to Slow Disability in Nonrelapsing Secondary MS
The Bruton's tyrosine kinase inhibitor tolebrutinib is reportedly the first agent to show benefit in patients with nonrelapsing secondary progressive MS.
Sanofi (SNY) ECTRIMS 2024 Investor Science Call Transcript
ECTRIMS 2024 Investor Science Call September 20, 2024 10:00 AM ETCompany ParticipantsThomas Kudsk - IRJiwon Oh - MD, PhD, St.
Monthly Prescribing Reference16d
Tolebrutinib Looks Promising for Patients With Non-Relapsing Secondary Progressive MS
Tolebrutinib was found to delay disability progression in patients with non-relapsing secondary progressive multiple sclerosis (nrSPMS), according to results from the HERCULES study.